Sinex%2520%2528oxymetazoline%2529

# Sinex (oxymetazoline) ## Overview - **Class:** Topical nasal decongestant (sympathomimetic, alpha-1 agonist). - **Common formulations:** 0.05% nasal spray (0.5 mg/mL). Available in regular, menthol, and pump spray forms. - **Mechanism:** Vasoconstriction of nasal mucosa, reducing edema and congestion. ## Primary Indications - Temporary relief of nasal congestion due to common cold, allergic rhinitis, sinusitis. ## Adult Dosing - **Spray:** 2–3 sprays per nostril every 10–12 hours. - **Maximum:** 2 doses per 24 hours (some protocols allow up to 3 but common max is 2). Do not exceed 3 days of continuous use. - Use for ≤3 days to minimize rebound congestion. ## Pediatric Dosing - **Age 6–12 years:** 1–2 sprays per nostril every 10–12 hours. Maximum 2 doses/24 hours. - **Age <6 years:** Safety and efficacy not established; avoid use. - If local protocol differs (e.g., pediatric-specific concentration 0.025%), follow that guidance. ## Dose Adjustments - No specific renal or hepatic adjustments needed for topical use. - If prolonged use (>3 days), a gradual dose reduction may help avoid rebound but is not standard. ## Contraindications - Narrow-angle glaucoma (especially untreated) - Concomitant or recent (within 14 days) MAO inhibitor therapy - Rhinitis sicca (dry, atrophic nasal mucosa) - Hypersensitivity to oxymetazoline or any component ## Adverse Effects - **Common:** Nasal burning, stinging, dryness, sneezing, transient congestion “rebound” after discontinuation if overused. - **Less common:** Anxiety, tremor, insomnia, palpitations, hypertension (with excessive use or systemic absorption). - **Long-term overuse:** Rhinitis medicamentosa (rebound congestion dependence). ## Key Drug Interactions - **MAO inhibitors** (e.g., phenelzine, selegiline): Risk of hypertensive crisis – contraindicated within 14 days. - **Other sympathomimetics** (oral decongestants, amphetamines): Additive cardiovascular effects. - **Beta-blockers (non-selective):** Can theoretically blunt vasoconstriction or lead to unopposed alpha effects – use caution. ## Monitoring - Duration of use (limit to ≤3 days) - Assess for rebound congestion, nasal irritation, or systemic amphetamine-like effects (especially in children or those with hypertension/cardiovascular disease) ## Clinical Pearls - 1 spray = approximately 0.1 mL of 0.05% solution (≈ 50 mcg oxymetazoline). 2–3 sprays deliver ~100–150 mcg per nostril. - Caution in patients with hypertension, heart disease, hyperthyroidism, or prostatic hyperplasia, though systemic absorption is minimal with proper use. - Avoid sharing spray bottles to prevent infection spread. - For pediatric use, some guidelines suggest 0.025% solution for ages 2–6; if only 0.05% is available, use the lowest number of sprays (1 spray per nostril) and limit to 3 days. --- **Disclaimer:** This information is for educational purposes only. Dosing may vary by local protocols and patient-specific factors. Always verify current prescribing information, especially for pediatric populations, and consult the complete product monograph.